Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 4, 2010 (rev. 1)


Raindance Technologies said this week that it has appointed Sirshendu Roopom Banerjee as president and CEO.

Banerjee was most recently director of healthcare investment banking at Leerink Swann, where he led the life science tools and diagnostics sector. Previously, Banerjee was with McKinsey and Goldman Sachs, where he advised Fortune 500 healthcare companies on corporate and growth strategy, product development, launch strategy, international expansion, and mergers and acquisitions.

Earlier in his career, Banerjee worked at Dana Farber Cancer Institute, the Whitehead Institute/MIT Human Genome Project, and the Massachusetts General Hospital Cancer Center. He holds a master's degree in public policy from the Kennedy School of Government at Harvard University and dual BS degrees in biology and economics from MIT.

Christopher McNary, who has served as RainDance CEO since Nov. 2007, will become chief commercial officer.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.